Eczema
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. with a confirmed diagnosis of chronic generalized eczema according to the diagnostic criteria; 2. the disease severity was at least moderate (Investigators Global Assessment score = 3); 3. the skin lesions were at multiple sites and affected 30% to 60% of the total body surface area; 4. the target lesions were at the limbs or trunk and showed a diameter of 2 cm to10 cm; 5. adult patients aged 18 to 80 years; 6. voluntarily signed the informed consent form.
Exclusion criteria
Exclusion criteria: 1. skin lesions were accompanied with infection of viruses, bacteria, and/or fungi; 2. the eczema were on the face and skin-folding areas; 3. systemic use of glucocorticoid and/or immunosuppressant, and/or ultraviolet light therapy within 4 weeks before the enrollment interview; 4. local use of glucocorticoid and/or oral use of antihistamines within two weeks before the enrollment interview; 5. with severe disease in the liver, kidney, and/or blood; 6. with autoimmune diseases, chronic serious infection, diabetes, mental diseases, substance abuse, and/or alcoholic; 7. with the malignant tumor or other serious diseases that may compromise the accuracy of efficacy evaluation for the study drug; 8. any other condition that the investigators believed could interfere in the study; 9. pregnant, breast-feeding, or plan to become pregnant during the study period; 10. allergic to the study drugs; 11. failed to follow the study protocol.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| EASI;adverse event;Efficacy index;serum cortisol (COR); | — |
Countries
China
Contacts
Department of Dermatology, Beijing Friendship Hospital, Capital Medical University